TL;DR
This study investigates the role of alpha-enolase (ENO1) in cutaneous melanoma, finding that its overexpression is linked to more aggressive tumor behavior and poorer patient prognosis. The research combines in vitro experiments with clinical data, suggesting ENO1 could be a valuable prognostic marker and a potential therapeutic target for melanoma.
What Problem Does This Paper Address?
Cutaneous melanoma is a significant health concern, and while advancements in treatment exist, identifying reliable prognostic markers and therapeutic targets remains crucial for improving patient outcomes. Alpha-enolase (ENO1), a glycolytic enzyme, has been implicated in the progression of various cancers, often correlating with poor prognosis. However, its specific role and prognostic significance in cutaneous melanoma were not well-established. This paper aims to fill that knowledge gap by investigating ENO1's expression, activity, and correlation with clinical and histopathological features in melanoma patients and cell lines.
Methods
The study employed a multi-pronged approach:
- In Vitro Studies:
- Cell Culture: Human epidermal melanocytes and several human melanoma cell lines (A375, Hs294T, WM9, WM1341D) were cultured under both normoxic and hypoxic conditions.
- Western Blotting: Used to assess ENO1 protein expression levels in cell lysates. Akt 1/2/3 was used as a loading control.
- Immunofluorescence: Visualized ENO1 expression within melanoma cells, focusing on its subcellular localization.
- Enolase Activity Assay: Measured the enzymatic activity of ENO1 in cell lysates, particularly comparing normoxic and hypoxic conditions.
- Clinical Study:
- Tissue Microarrays (TMAs): Constructed from surgical resections of 112 primary cutaneous melanoma patients.
- Immunohistochemistry (IHC): Performed on TMAs to evaluate ENO1 protein expression in tumor tissues. An H-score was used to quantify expression levels, categorizing patients into "low" and "high" ENO1 expression groups.
- Statistical Analysis: A range of statistical methods were used, including Wilcoxon two-sample tests, Fisher's exact tests, chi-square tests, Kaplan-Meier survival analysis, log-rank tests, and univariate Cox proportional hazards models to correlate ENO1 expression with clinical and histopathological parameters, as well as patient survival.
Datasets
- Melanoma Cell Lines: A375, Hs294T, WM9, and WM1341D were used for in vitro experiments.
- Normal Melanocytes: Human epidermal melanocytes (HEMa and HEMn-LP) served as a control for in vitro studies.
- Clinical Patient Cohort: Data from 112 primary cutaneous melanoma patients treated at the Regional Oncology Centre in Opole, Poland, diagnosed between 2005 and 2010, were used for the clinical study. This dataset included comprehensive clinical and histopathological information.
Key Insights and Ideas
- ENO1 is Overexpressed in Melanoma Cells: Both in vitro and clinical analyses consistently showed higher ENO1 expression in melanoma cells compared to normal melanocytes.
- Hypoxia Enhances ENO1 Activity in Metastatic Cells: While ENO1 expression was generally high, its enzymatic activity was significantly boosted under hypoxic conditions in cell lines derived from lymph node metastases, suggesting a role in adapting to the microenvironment of secondary tumors.
- ENO1 Expression is a Strong Prognostic Indicator: High ENO1 expression in tumor cells was significantly associated with multiple unfavorable prognostic factors, including advanced tumor stage, presence of lymph node metastases, and higher Breslow thickness and Clark levels.
- ENO1 Predicts Worse Survival: Patients with high ENO1 expression had a demonstrably shorter cancer-specific overall survival and disease-free survival.
- ENO1 as a Potential Therapeutic Target: The findings strongly suggest that ENO1's role in promoting melanoma invasiveness and aggressive behavior makes it a promising candidate for further investigation as a therapeutic target.
Key Results
- In Vitro:
- Melanoma cell lines (A375, Hs294T, WM9, WM1341D) showed significantly higher ENO1 expression than normal melanocytes.
- ENO1 activity increased under hypoxia in WM9 and Hs294T (metastatic) cell lines, but not in A375 and WM1341D (primary tumor) cell lines.
- Clinical:
- Out of 112 patients, 50% (56 patients) showed low ENO1 expression (H-score ≤200), and 50% (56 patients) showed high ENO1 expression (H-score >200).
- High ENO1 expression was significantly correlated with advanced AJCC stage (p < 0.001), presence of regional lymph node metastases (p = 0.007), and recurrence (p = 0.018).
- Histopathologically, high ENO1 expression correlated with higher Breslow thickness (p < 0.001), higher Clark level (p < 0.001), increased mitotic rate (p < 0.001), and ulceration (p = 0.013). Nodular melanomas showed the highest ENO1 expression.
- Kaplan-Meier analysis showed that overexpression of ENO1 was associated with significantly shorter cancer-specific overall survival (p = 0.023) and disease-free survival (p = 0.001).
- Univariate Cox regression analysis identified high ENO1 H-score as an independent prognostic factor for shorter DFS (HR = 2.6, p = 0.005).
Limitations and Future Work
- Limitations:
- The study acknowledges that in multivariable Cox regression, after adjusting for key parameters like nodal status, ENO1 did not reach statistical significance for DFS. This suggests that while ENO1 is a strong univariate predictor, its independent prognostic value might be influenced by other established factors.
- The study focused on a specific cohort of patients from Poland; broader validation across diverse populations would strengthen the findings.
- While the study explored ENO1's role in invasiveness, the precise molecular mechanisms by which ENO1 promotes these processes in melanoma require further elucidation.
- Future Work:
- The authors suggest that ENO1 is a promising candidate for further research as a prognostic marker and a therapeutic target in cutaneous melanoma.
- Investigating the influence of alternatively spliced nuclear isoforms of ENO1, such as MBP-1, on melanoma cell proliferation and invasion is proposed.
- Further studies are needed to explore the therapeutic potential of targeting ENO1, potentially through monoclonal antibodies or other inhibitory strategies.
Summary updated